Review



antibody against human lambda light chain  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier
Bioz Manufacturer Symbol Bio-Rad manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Bio-Rad antibody against human lambda light chain
    Schematic representation of the recombinant measles virus (MV) strains used in the experiments: <t>MV-lambda,</t> <t>MV-lambda-NAP,</t> MV-s-NAP and MV-NIS. NAP, neutrophil-activating protein.
    Antibody Against Human Lambda Light Chain, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 86/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/free+human+ig+lambda+light+chains/Mouse+anti+Human+Lambda+Light+Chain/pmc03369290-313-17-7
    Average 86 stars, based on 4 article reviews
    antibody against human lambda light chain - by Bioz Stars, 2026-10
    86/100 stars

    Images

    1) Product Images from "Expression of Immunomodulatory Neutrophil-activating Protein of Helicobacter pylori Enhances the Antitumor Activity of Oncolytic Measles Virus"

    Article Title: Expression of Immunomodulatory Neutrophil-activating Protein of Helicobacter pylori Enhances the Antitumor Activity of Oncolytic Measles Virus

    Journal: Molecular Therapy

    doi: 10.1038/mt.2012.4

    Schematic representation of the recombinant measles virus (MV) strains used in the experiments: MV-lambda, MV-lambda-NAP, MV-s-NAP and MV-NIS. NAP, neutrophil-activating protein.
    Figure Legend Snippet: Schematic representation of the recombinant measles virus (MV) strains used in the experiments: MV-lambda, MV-lambda-NAP, MV-s-NAP and MV-NIS. NAP, neutrophil-activating protein.

    Techniques Used: Recombinant, Virus

    In vitro antitumor activity of engineered measles virus (MV) strains against breast cancer cells. (a) MCF-7 cell line and the highly tumorigenic MDA231-lu-P4 in vivo derivative of (b) MDA-MB-231 cells were infected with MV strains at an multiplicity of infection (MOI) = 1.0 and cell viability was determined by MTT assay. Both MV-lambda-NAP and MV-lambda viruses propagated rapidly causing complete destruction of the breast cancer monolayers 72 hours postinfection. MV-s-NAP and MV-NIS showed similar tumor cell-killing kinetics with complete eradication of MCF-7 cells or ~80% reduction of cell viability of MDA231-lu-P4 cells. (c) Vero cells were used as control. The data are presented as percent of untreated control cells ± SD. (d) NAP transgene induced significant interleukin (IL)-8 expression in MV vector-infected THP-1 cells. THP-1 monocytic cells were infected with MV-s-NAP or control MV-lambda virus at a MOI = 0.1 and incubated for 72 hours. Supernatants were collected and IL-8 concentration was measured by enzyme-linked immunosorbent assay (ELISA) specific for human IL-8. The effect of TNF-α (one of the known NAP-triggered inflammatory cytokines) on proliferation of MV-infected or uninfected MDA231-lu-P4 cells was examined by MTT assay (e,f). MDA231-lu-P4 cells were plated at 104 cell/well density and inoculated at MOI = 0.5 of MV-s-NAP in the presence or absence of 250 U/ml recombinant human TNF-α (e). The same experiment was repeated with lower cell density (2.5 × 103 per well) and MV-s-NAP at MOI of 0.25 (f).
    Figure Legend Snippet: In vitro antitumor activity of engineered measles virus (MV) strains against breast cancer cells. (a) MCF-7 cell line and the highly tumorigenic MDA231-lu-P4 in vivo derivative of (b) MDA-MB-231 cells were infected with MV strains at an multiplicity of infection (MOI) = 1.0 and cell viability was determined by MTT assay. Both MV-lambda-NAP and MV-lambda viruses propagated rapidly causing complete destruction of the breast cancer monolayers 72 hours postinfection. MV-s-NAP and MV-NIS showed similar tumor cell-killing kinetics with complete eradication of MCF-7 cells or ~80% reduction of cell viability of MDA231-lu-P4 cells. (c) Vero cells were used as control. The data are presented as percent of untreated control cells ± SD. (d) NAP transgene induced significant interleukin (IL)-8 expression in MV vector-infected THP-1 cells. THP-1 monocytic cells were infected with MV-s-NAP or control MV-lambda virus at a MOI = 0.1 and incubated for 72 hours. Supernatants were collected and IL-8 concentration was measured by enzyme-linked immunosorbent assay (ELISA) specific for human IL-8. The effect of TNF-α (one of the known NAP-triggered inflammatory cytokines) on proliferation of MV-infected or uninfected MDA231-lu-P4 cells was examined by MTT assay (e,f). MDA231-lu-P4 cells were plated at 104 cell/well density and inoculated at MOI = 0.5 of MV-s-NAP in the presence or absence of 250 U/ml recombinant human TNF-α (e). The same experiment was repeated with lower cell density (2.5 × 103 per well) and MV-s-NAP at MOI of 0.25 (f).

    Techniques Used: In Vitro, Activity Assay, Virus, In Vivo, Infection, MTT Assay, Control, Expressing, Plasmid Preparation, Incubation, Concentration Assay, Enzyme-linked Immunosorbent Assay, Recombinant

    Measles virus (MV) infection and neutrophil-activating protein (NAP) transgene expression in the malignant pleural effusion of mice-bearing MDA231-lu-P4 pleural xenografts. Mice were treated by a single transthoracic (t.t.). injection of MV-s-NAP or MV-lambda. NAP transgene expression in pleural fluid was demonstrated by immunoblotting using (a) NAP-specific monoclonal antibody (MAb) 16F4 or (b) lambda chain-specific antibody. The secretory form of the NAP transgene was detected in the pleural fluid of four of four MV-s-NAP-treated mice (lanes 1–4) but not in MV-lambda-injected (lanes 5, 6) control mice (a). Human lambda light chain was detected in three of four samples from MV-lambda-injected (lanes 3–6) mice but not in samples from MV-s-NAP-treated (lanes 1, 2) animals (b) using a lambda chain-specific detection antibody. MV-s-NAP (c) induced large multinucleated syncytia in infected tumor cells (Giemsa staining) in the pleural fluid of mice with MDA231-lu-P4 xenografts. Immunohistochemistry (IHC) staining for neutrophils in the pleural fluid of MV-s-NAP is shown in (d). MV-s-NAP was isolated from the pleural fluid by overlay on Vero cells. MV-s-NAP induced giant syncytia formation 24 hours after overlay (e). Uninfected control Vero cells (f).
    Figure Legend Snippet: Measles virus (MV) infection and neutrophil-activating protein (NAP) transgene expression in the malignant pleural effusion of mice-bearing MDA231-lu-P4 pleural xenografts. Mice were treated by a single transthoracic (t.t.). injection of MV-s-NAP or MV-lambda. NAP transgene expression in pleural fluid was demonstrated by immunoblotting using (a) NAP-specific monoclonal antibody (MAb) 16F4 or (b) lambda chain-specific antibody. The secretory form of the NAP transgene was detected in the pleural fluid of four of four MV-s-NAP-treated mice (lanes 1–4) but not in MV-lambda-injected (lanes 5, 6) control mice (a). Human lambda light chain was detected in three of four samples from MV-lambda-injected (lanes 3–6) mice but not in samples from MV-s-NAP-treated (lanes 1, 2) animals (b) using a lambda chain-specific detection antibody. MV-s-NAP (c) induced large multinucleated syncytia in infected tumor cells (Giemsa staining) in the pleural fluid of mice with MDA231-lu-P4 xenografts. Immunohistochemistry (IHC) staining for neutrophils in the pleural fluid of MV-s-NAP is shown in (d). MV-s-NAP was isolated from the pleural fluid by overlay on Vero cells. MV-s-NAP induced giant syncytia formation 24 hours after overlay (e). Uninfected control Vero cells (f).

    Techniques Used: Virus, Infection, Expressing, Injection, Western Blot, Control, Staining, Immunohistochemistry, Isolation

    Therapeutic effect of neutrophil-activating protein (NAP)-expressing measles virus (MV) strains against lung metastatic breast cancer compared to control MV-NIS. (a) Engraftment of the systemically injected MDA231-lu-P3 or P4 cells was confirmed by bioluminescence imaging. (b,c) The animals with MDA231-lu-P3 lung tumors (8 per group) were treated with 10 repeat intravenous (i.v.) injections of 2 × 106 TCID50 of MV-lambda-NAP or heat-inactivated (HI-control) control. In a separate in vivo experiment MDA231-lu-P4 lung metastatic xenografts (9 mice per group) were treated by 7 i.v. injections of 106 TCID50 of MV-s-NAP, MV-NIS or the corresponding heat-inactivated controls (d–f). Both MV-lambda-NAP and MV-s-NAP improved the median survival with 10–12 days (P < 0.05) in this aggressive model of breast cancer metastatic to the lungs.
    Figure Legend Snippet: Therapeutic effect of neutrophil-activating protein (NAP)-expressing measles virus (MV) strains against lung metastatic breast cancer compared to control MV-NIS. (a) Engraftment of the systemically injected MDA231-lu-P3 or P4 cells was confirmed by bioluminescence imaging. (b,c) The animals with MDA231-lu-P3 lung tumors (8 per group) were treated with 10 repeat intravenous (i.v.) injections of 2 × 106 TCID50 of MV-lambda-NAP or heat-inactivated (HI-control) control. In a separate in vivo experiment MDA231-lu-P4 lung metastatic xenografts (9 mice per group) were treated by 7 i.v. injections of 106 TCID50 of MV-s-NAP, MV-NIS or the corresponding heat-inactivated controls (d–f). Both MV-lambda-NAP and MV-s-NAP improved the median survival with 10–12 days (P < 0.05) in this aggressive model of breast cancer metastatic to the lungs.

    Techniques Used: Expressing, Virus, Control, Injection, Imaging, In Vivo

    Related Articles

    Membrane:

    Article Title: Expression of Immunomodulatory Neutrophil-activating Protein of Helicobacter pylori Enhances the Antitumor Activity of Oncolytic Measles Virus
    Article Snippet: Briefly, 10 μl of 1:10 diluted in PBS pleural fluid were mixed with 10 μl sample buffer and were resolved on 15% Criterion gel (Bio-Rad, Hercules, CA). .. Proteins were transferred to polyvinylidene fluoride membrane (Bio-Rad) and probed with the NAP-specific monoclonal antibody 16F4 or antibody against human lambda light chain as previously described. ..



    Similar Products

    human igg concentrations  (Bio-Rad)
    91
    Bio-Rad human igg concentrations
    Human Igg Concentrations, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/free+human+ig+lambda+light+chains/Mouse+anti+Human+Ig+Lambda+Light+Chain+(Bound+%2B+Free)/pmc10382333-78-20-35
    Average 91 stars, based on 1 article reviews
    human igg concentrations - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier
    free human ig lambda light chains  (Bethyl)
    93
    Bethyl free human ig lambda light chains
    Free Human Ig Lambda Light Chains, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/free+human+ig+lambda+light+chains/Human+Lambda+Free+Light+Chain/bio_rxiv__2022__09__25__509440-91-25-40
    Average 93 stars, based on 1 article reviews
    free human ig lambda light chains - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    human ig λ light chain  (Bethyl)
    93
    Bethyl human ig λ light chain
    Runx2 knockdown inhibits MM progression in vivo. (A) Expression of Runx2 in 2 Runx2 k/d 5TGM1 cell lines (Runx2 shRNA #90– and Runx2 shRNA #91–transfected 5TGM1 cells) was probed by western blot. Both Runx2 shRNA #90 and #91 decreased the expression of Runx2 compared with NT control. (B) Serum IgG2bκ was measured by ELISA 6 weeks after IV injection of NT control or Runx2 k/d 5TGM1 cells. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (C) H&E-stained bone sections from mice injected IV with either NT control or Runx2 k/d 5TGM1 cells. Tumors were present in mice injected with NT cells, but not in the mice injected with Runx2 k/d cells (original magnification, ×100). Inset, Abundant myeloma cells in NT-bearing mice compared with Runx2 k/d 5TGM1 cell-injected mice. (D) Survival was significantly increased in mice injected IV with 5TGM1 Runx2 k/d cells (clone #90 and #91) compared with those injected with NT 5TGM1 cells. (E) Six weeks after intratibial injection of Runx2 k/d or NT 5TGM1 cells, levels of serum IgG2bκ were measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (F) Western blot shows reduction of Runx2 expression in MM.1R cells transduced with Runx2 shRNA compared with wild-type (WT) or NT control cells. (G) Six weeks after s.c. injection of NT or Runx2 k/d human MM.1R cells, serum human Ig <t>λ</t> <t>light</t> chain was measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value.
    Human Ig λ Light Chain, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/free+human+ig+lambda+light+chains/Human+Lambda+Free+Light+Chain/pmc04458799-137-3-25
    Average 93 stars, based on 1 article reviews
    human ig λ light chain - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    mouse anti human histone h1 monoclonal antibody ae 4  (Bio-Rad)
    91
    Bio-Rad mouse anti human histone h1 monoclonal antibody ae 4
    Runx2 knockdown inhibits MM progression in vivo. (A) Expression of Runx2 in 2 Runx2 k/d 5TGM1 cell lines (Runx2 shRNA #90– and Runx2 shRNA #91–transfected 5TGM1 cells) was probed by western blot. Both Runx2 shRNA #90 and #91 decreased the expression of Runx2 compared with NT control. (B) Serum IgG2bκ was measured by ELISA 6 weeks after IV injection of NT control or Runx2 k/d 5TGM1 cells. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (C) H&E-stained bone sections from mice injected IV with either NT control or Runx2 k/d 5TGM1 cells. Tumors were present in mice injected with NT cells, but not in the mice injected with Runx2 k/d cells (original magnification, ×100). Inset, Abundant myeloma cells in NT-bearing mice compared with Runx2 k/d 5TGM1 cell-injected mice. (D) Survival was significantly increased in mice injected IV with 5TGM1 Runx2 k/d cells (clone #90 and #91) compared with those injected with NT 5TGM1 cells. (E) Six weeks after intratibial injection of Runx2 k/d or NT 5TGM1 cells, levels of serum IgG2bκ were measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (F) Western blot shows reduction of Runx2 expression in MM.1R cells transduced with Runx2 shRNA compared with wild-type (WT) or NT control cells. (G) Six weeks after s.c. injection of NT or Runx2 k/d human MM.1R cells, serum human Ig <t>λ</t> <t>light</t> chain was measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value.
    Mouse Anti Human Histone H1 Monoclonal Antibody Ae 4, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/free+human+ig+lambda+light+chains/Mouse+anti+Human+Ig+Lambda+Light+Chain+(Bound+%2B+Free)/pm19083849-63-34-41
    Average 91 stars, based on 1 article reviews
    mouse anti human histone h1 monoclonal antibody ae 4 - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Runx2 knockdown inhibits MM progression in vivo. (A) Expression of Runx2 in 2 Runx2 k/d 5TGM1 cell lines (Runx2 shRNA #90– and Runx2 shRNA #91–transfected 5TGM1 cells) was probed by western blot. Both Runx2 shRNA #90 and #91 decreased the expression of Runx2 compared with NT control. (B) Serum IgG2bκ was measured by ELISA 6 weeks after IV injection of NT control or Runx2 k/d 5TGM1 cells. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (C) H&E-stained bone sections from mice injected IV with either NT control or Runx2 k/d 5TGM1 cells. Tumors were present in mice injected with NT cells, but not in the mice injected with Runx2 k/d cells (original magnification, ×100). Inset, Abundant myeloma cells in NT-bearing mice compared with Runx2 k/d 5TGM1 cell-injected mice. (D) Survival was significantly increased in mice injected IV with 5TGM1 Runx2 k/d cells (clone #90 and #91) compared with those injected with NT 5TGM1 cells. (E) Six weeks after intratibial injection of Runx2 k/d or NT 5TGM1 cells, levels of serum IgG2bκ were measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (F) Western blot shows reduction of Runx2 expression in MM.1R cells transduced with Runx2 shRNA compared with wild-type (WT) or NT control cells. (G) Six weeks after s.c. injection of NT or Runx2 k/d human MM.1R cells, serum human Ig λ light chain was measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value.

    Journal: Blood

    Article Title: Myeloma cell–derived Runx2 promotes myeloma progression in bone

    doi: 10.1182/blood-2014-12-613968

    Figure Lengend Snippet: Runx2 knockdown inhibits MM progression in vivo. (A) Expression of Runx2 in 2 Runx2 k/d 5TGM1 cell lines (Runx2 shRNA #90– and Runx2 shRNA #91–transfected 5TGM1 cells) was probed by western blot. Both Runx2 shRNA #90 and #91 decreased the expression of Runx2 compared with NT control. (B) Serum IgG2bκ was measured by ELISA 6 weeks after IV injection of NT control or Runx2 k/d 5TGM1 cells. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (C) H&E-stained bone sections from mice injected IV with either NT control or Runx2 k/d 5TGM1 cells. Tumors were present in mice injected with NT cells, but not in the mice injected with Runx2 k/d cells (original magnification, ×100). Inset, Abundant myeloma cells in NT-bearing mice compared with Runx2 k/d 5TGM1 cell-injected mice. (D) Survival was significantly increased in mice injected IV with 5TGM1 Runx2 k/d cells (clone #90 and #91) compared with those injected with NT 5TGM1 cells. (E) Six weeks after intratibial injection of Runx2 k/d or NT 5TGM1 cells, levels of serum IgG2bκ were measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (F) Western blot shows reduction of Runx2 expression in MM.1R cells transduced with Runx2 shRNA compared with wild-type (WT) or NT control cells. (G) Six weeks after s.c. injection of NT or Runx2 k/d human MM.1R cells, serum human Ig λ light chain was measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value.

    Article Snippet: The levels of human Ig λ light chain or mouse IgG2bκ in mouse sera were measured using human Ig λ or mouse IgG2bκ ELISA kits (Bethyl Laboratories Inc), respectively.

    Techniques: Knockdown, In Vivo, Expressing, shRNA, Transfection, Western Blot, Control, Enzyme-linked Immunosorbent Assay, IV Injection, Staining, Injection, Transduction